Amphastar Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Amphastar Pharma (AMPH).

Price Target Range — 12 Quarters

Analyst Consensus — 5 Analysts

4Hold

1Sell

Consensus RatingOverweight# Analysts5Avg. Consensus PT$28Upside to Avg. PT+7.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 18, 2026	Barclays	Glen Santangelo	PT Raise	Equal-Weight	$20→$23
Aug 7, 2026	Piper Sandler	David Amsellem	PT Cut	Neutral	$21→$20
Aug 7, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Equal-Weight	$19→$20
Jun 29, 2026	B of A Securities	Jason Gerberry	Downgrade	Neutral→Underperform	$25→$20
Jun 3, 2026	Barclays	Glen Santangelo	PT Cut	Equal-Weight	$23→$20
May 14, 2026	Wells Fargo	Benjamin Burnett	Downgrade	Overweight→Equal-Weight	$30→$19
May 11, 2026	Piper Sandler	David Amsellem	PT Cut	Neutral	$25→$21
May 8, 2026	Needham	Serge Belanger	Downgrade	Buy→Hold	—
Apr 21, 2026	Jefferies	Dennis Ding	Downgrade	Buy→Hold	$30→$22
Apr 8, 2026	Barclays	Glen Santangelo	PT Cut	Equal-Weight	$30→$23
Feb 27, 2026	Wells Fargo	Benjamin Burnett	PT Cut	Overweight	$34→$30
Feb 27, 2026	Needham	Serge Belanger	PT Cut	Buy	$34→$30
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Equal-Weight	$30
Nov 7, 2025	Needham	Serge Belanger	PT Cut	Buy	$36→$34
Oct 22, 2025	Needham	Serge Belanger	Maintained	Buy	$36
Aug 26, 2025	B of A Securities	Jason Gerberry	PT Raise	Neutral	$28→$32
Aug 12, 2025	Needham	Serge Belanger	Upgrade	Hold→Buy	$36
Aug 8, 2025	Piper Sandler	David Amsellem	PT Cut	Neutral	$30→$25
May 12, 2025	JP Morgan	Ekaterina Knyazkova	Downgrade	Overweight→Neutral	$45→$30
May 8, 2025	Wells Fargo	Cerena Chen	PT Cut	Overweight	$40→$35

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Maintains Neutral on Amphastar Pharma, Lowers Price Target to $20

Piper Sandler analyst David Amsellem maintains Amphastar Pharma (NASDAQ:AMPH) with a Neutral and lowers the price target from $21 to $20.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Amphastar Pharma, Raises Price Target to $20

Wells Fargo analyst Benjamin Burnett maintains Amphastar Pharma (NASDAQ:AMPH) with a Equal-Weight and raises the price target from $19 to $20.

Benzinga Newsdesk

This Liquidia Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Top Wall Street analysts changed outlook on top stocks. See all changes including upgrades, downgrades, and initiations on analyst ratings page.

Avi Kapoor

PRO
B of A Securities Downgrades Amphastar Pharma to Underperform, Lowers Price Target to $20

B of A Securities analyst Jason Gerberry downgrades Amphastar Pharma (NASDAQ:AMPH) from Neutral to Underperform and lowers the price target from $25 to $20.

Benzinga Newsdesk

PRO
Barclays Maintains Equal-Weight on Amphastar Pharma, Lowers Price Target to $20

Barclays analyst Glen Santangelo maintains Amphastar Pharma (NASDAQ:AMPH) with a Equal-Weight and lowers the price target from $23 to $20.

Benzinga Newsdesk

PRO
Wells Fargo Downgrades Amphastar Pharma to Equal-Weight, Lowers Price Target to $19

Wells Fargo analyst Benjamin Burnett downgrades Amphastar Pharma (NASDAQ:AMPH) from Overweight to Equal-Weight and lowers the price target from $30 to $19.

Benzinga Newsdesk

Amphastar Pharmaceuticals Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Amphastar Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Piper Sandler Maintains Neutral on Amphastar Pharma, Lowers Price Target to $20

PRO
Wells Fargo Maintains Equal-Weight on Amphastar Pharma, Raises Price Target to $20

This Liquidia Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

PRO
B of A Securities Downgrades Amphastar Pharma to Underperform, Lowers Price Target to $20

PRO
Barclays Maintains Equal-Weight on Amphastar Pharma, Lowers Price Target to $20

PRO
Wells Fargo Downgrades Amphastar Pharma to Equal-Weight, Lowers Price Target to $19

People Also Watch

People Also Watch

Amphastar Pharmaceuticals Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Amphastar Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROPiper Sandler Maintains Neutral on Amphastar Pharma, Lowers Price Target to $20

PROWells Fargo Maintains Equal-Weight on Amphastar Pharma, Raises Price Target to $20

This Liquidia Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

PROB of A Securities Downgrades Amphastar Pharma to Underperform, Lowers Price Target to $20

PROBarclays Maintains Equal-Weight on Amphastar Pharma, Lowers Price Target to $20

PROWells Fargo Downgrades Amphastar Pharma to Equal-Weight, Lowers Price Target to $19

People Also Watch

People Also Watch

PRO
Piper Sandler Maintains Neutral on Amphastar Pharma, Lowers Price Target to $20

PRO
Wells Fargo Maintains Equal-Weight on Amphastar Pharma, Raises Price Target to $20

PRO
B of A Securities Downgrades Amphastar Pharma to Underperform, Lowers Price Target to $20

PRO
Barclays Maintains Equal-Weight on Amphastar Pharma, Lowers Price Target to $20

PRO
Wells Fargo Downgrades Amphastar Pharma to Equal-Weight, Lowers Price Target to $19